ADAR1 Capital Management, LLC - 14 Sep 2026 Form 4 Insider Report for InMed Pharmaceuticals Inc. (INM)

Reporting relationship: 10%+ Owner
Issuer ticker: INM
Reported as of: 14 Sep 2026
Net transaction value: +$118,076
SEC form: 4
Accepted by SEC: 16 Sep 2026, 18:58:22 UTC
Prior SEC filing: 08 Sep 2026
Source filing: View source filing
Reporting owner signature: ADAR1 Capital Management, LLC By: Daniel Schneeberger, Manager /s/ Daniel Schneeberger

Key filing fact

ADAR1 Capital Management, LLC filed Form 4 for InMed Pharmaceuticals Inc. (INM) on 16 Sep 2026.

Key facts

This page summarizes ADAR1 Capital Management, LLC's Form 4 filing for InMed Pharmaceuticals Inc. (INM).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 16 Sep 2026, 18:58.

Change

Previous filing in this sequence was filed on 08 Sep 2026.
Current net transaction value: +$118,076.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0001940272 Primary reporting owner

ADAR1 Capital Management, LLC

Relationship: 10%+ Owner
Address: 3503 WILD CHERRY DRIVE, BUILDING 9, AUSTIN
Signature: ADAR1 Capital Management, LLC By: Daniel Schneeberger, Manager /s/ Daniel Schneeberger
Signature date: 16 Sep 2026

CIK 0001861120

Schneeberger Daniel

Relationship: 10%+ Owner
Address: 3503 WILD CHERRY DRIVE, BUILDING 9, AUSTIN
Signature: /s/ Daniel Schneeberger
Signature date: 16 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INM transaction

Common Shares

Purchase

Transaction value: $36,880
Shares: +28,505
Change %: +3.6%
Price: $1.29
Shares after: 829,505
Date: 14 Sep 2026
Ownership: See Footnote
Footnotes: F1, F4, F5

INM transaction

Common Shares

Purchase

Transaction value: $36,880
Shares: +28,505
Change %: +3.6%
Price: $1.29
Shares after: 829,505
Date: 14 Sep 2026
Ownership: See Footnote
Footnotes: F1, F4, F5

INM transaction

Common Shares

Purchase

Transaction value: $70,446
Shares: +54,256
Change %: +6.5%
Price: $1.30
Shares after: 883,761
Date: 15 Sep 2026
Ownership: See Footnote
Footnotes: F2, F4, F5

INM transaction

Common Shares

Purchase

Transaction value: $70,446
Shares: +54,256
Change %: +6.5%
Price: $1.30
Shares after: 883,761
Date: 15 Sep 2026
Ownership: See Footnote
Footnotes: F2, F4, F5

INM transaction

Common Shares

Purchase

Transaction value: $10,750
Shares: +8,340
Change %: +0.94%
Price: $1.29
Shares after: 892,101
Date: 16 Sep 2026
Ownership: See Footnote
Footnotes: F3, F4, F5

INM transaction

Common Shares

Purchase

Transaction value: $10,750
Shares: +8,340
Change %: +0.94%
Price: $1.29
Shares after: 892,101
Date: 16 Sep 2026
Ownership: See Footnote
Footnotes: F3, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.2900 to $1.3100, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Footnote F2

The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.2800 to $1.3000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Footnote F3

The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.2600 to $1.3000, inclusive. Each Reporting Person undertakes to provide to InMed Pharmaceuticals Inc., any security holder of InMed Pharmaceuticals Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.

Footnote F4

The reported securities are owned directly by private investment funds managed by ADAR1 Capital Management, LLC, and may be deemed to be indirectly beneficially owned by (i) ADAR1 Capital Management, LLC and (ii) Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC.

Footnote F5

For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.